Radiotherapy combined with first-line anti-programmed cell death protein 1 (PD-1) immunotherapy and chemotherapy for patients with advanced non-small cell lung cancer: A bicentric retrospective study
Radiotherapy is safe and manageable when added to first-line anti-PD-1 immunotherapy and chemotherapy for patients with advanced NSCLC.
Authors
- Ruiguang Zhang
- Xiaohua Jie (ORCID: https://orcid.org/0000-0002-5841-5976)
- Ling Peng (ORCID: https://orcid.org/0000-0003-2465-9056)
- Pian Liu (ORCID: https://orcid.org/0000-0001-5780-3902)
- Gang Wu (ORCID: https://orcid.org/0000-0001-5930-6715)
- Jian Wang (ORCID: https://orcid.org/0000-0002-6768-5986)
- Sheng Zhang (ORCID: https://orcid.org/0000-0003-0843-0622)
- Xiaorong Dong
- Yongchang Zhang (ORCID: https://orcid.org/0000-0002-6829-7176)
- Peng Ding (ORCID: https://orcid.org/0009-0006-4426-7833)
- Fan Tong (ORCID: https://orcid.org/0000-0002-4588-8520)
- Yu Huang
- Shishi Cheng
- Nong Yang
Institutions
- Union Hospital (HK)
- Central South University (CN)
- Second People Hospital of Hunan (CN)
- Hunan Cancer Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Cancer Pathogenesis and Therapy
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.cpt.2025.02.007
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00